Innoviva (INVA) unit Innoviva Specialty Therapeutics said Monday it signed an exclusive licensing and distribution deal with Basilea Pharmaceutica for US marketing rights to the antibiotic Zevtera or ceftobiprole.
The company, which plans to launch Zevtera in the US by mid-2025, said it will pay Basilea $4 million upfront, with additional royalties and sales milestones.
Basilea said in a separate statement that it expects to receive sales milestones of up to $223 million.
Zevtera, approved by the US Food and Drug Administration in April, is the only cephalosporin cleared for treating methicillin-resistant Staphylococcus aureus, or MRSA, bloodstream infections and endocarditis in adults.
The drug is also approved for other bacterial infections, including skin infections in adults and pneumonia in patients aged three months to 18 years, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。